News
FoldRx to be acquired by Pfizer
September 1, 2010 6:37 am | by Mass High Tech: The Journal of New England Technology | CommentsCambridge small molecule therapeutics firm FoldRx Pharmaceuticals Inc. is going to be acquired by pharmaceutical giant Pfizer Inc. as part of the latter company’s overall strategy to increase its pipeline of drugs to treat rare diseases.
<i>Tech across New England: </i>ProThera Biologics takes holistic approach to treating inflammation
September 1, 2010 6:34 am | by Mass High Tech: The Journal of New England Technology | CommentsMass High Tech looked at startups poised to lead the economic recovery because of their technology, management team or growth potential. ProThera Biologics develops technology centered on a protein in the blood that regulates the immune system and is the key to controlling sepsis...
PerkinElmer pulls in $500M from sales of IDS unit
September 1, 2010 6:32 am | by Mass High Tech: The Journal of New England Technology | CommentsIn its latest move of adding or subtracting business lines, PerkinElmer Inc. reports it has agreed to sell its Illumination and Detection Solutions (IDS) business to Veritas Capital Fund III LP, a New York-based private equity firm, for approximately $500 million in cash.
Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
September 1, 2010 4:33 am | by Bio-Medicine.Org | CommentsLONDON, Sept. 1 /- The pharmacy automation systems market in Europe is experiencing a tremendous growth spurt. Until recently, most pharmacies have been either without automation or have employed very basic automation systems. In response, the adoption rate of automation systems across...
St. Jude Children's Research Hospital Doctors and Scientists Team up to Fight Childhood Cancer
September 1, 2010 4:32 am | by Bio-Medicine.Org | CommentsMEMPHIS, Tenn., Sept. 1 /PRNewswire-USNewswire/ -- Survival rates overall for childhood cancer are almost 80 percent—a marked advance against a disease that was curable in only a small fraction of children 50 years ago. However, despite progress, pediatric cancer remains the leading...
Covidien Announces Investor Meeting Agenda
September 1, 2010 3:32 am | by Covidien | CommentsDUBLIN, Sep 01, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the agenda for its investor meeting on Wednesday, September 15, 2010. The event will be held at The Plaza Hotel, Fifth Avenue at Central Park South, New York, NY....
JDSU expands into solar and gaming markets
August 31, 2010 10:33 pm | by I-Micronews | CommentsThe diversified optical technologies company is expanding production of components used in new "gesture recognition" games consoles.
SCHOTT Solar and Solland Solar sign partnership agreement
August 31, 2010 10:33 pm | by I-Micronews | CommentsSCHOTT Solar and Solland Solar signed a partnership agreement that comprises technology license agreements, joint R&D efforts and joint production for back-contacted solar modules.
New device packs power to analyze genes, proteins at patients' bedside
August 31, 2010 10:32 pm | by I-Micronews | CommentsUniversity of Florida researchers have helped to develop a device that quickly identifies genes and proteins in body fluids, a technique that could make a vital difference to the trauma patients doctors treat.
<i>Tech across New England: </i>Stromatec devices made to treat connective tissue problems
August 31, 2010 10:32 pm | by Mass High Tech: The Journal of New England Technology | CommentsMass High Tech looked at startups poised to lead the economic recovery because of their technology, management team or growth potential. Stromatec specializes in medical devices that could help reduce health care costs by preventing unnecessary MRIs and even unnecessary surgery, by...
<i>Tech across New England: </i>EpiVax poised to lead vaccine developments
August 31, 2010 9:33 pm | by Mass High Tech: The Journal of New England Technology | CommentsMass High Tech looked at startups poised to lead the economic recovery because of their technology, management team or growth potential. EpiVax applies its tools to screening proteins for unwanted immune responses and using these tools to design and deimmunize protein therapeutics and vaccines.
Lung cancer survival rates improved through use of individualized chemotherapy
August 31, 2010 9:32 pm | by EurekAlert | Comments(International Association for the Study of Lung Cancer) Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing...
Tumor budding identified as predictor for unfavorable outcome in lung cancer
August 31, 2010 9:32 pm | by EurekAlert | Comments(International Association for the Study of Lung Cancer) Lung cancer is the leading cause of cancer deaths worldwide, and the prognosis is generally poor, even if surgery is successful. Furthermore, the incidence of one type of lung cancer, adenocarcinoma, has been increasing in recent years.
<i>Tech across New England: </i>Cara Therapeutics aims to rid side effects of pain relief
August 31, 2010 8:34 pm | by Mass High Tech: The Journal of New England Technology | CommentsMass High Tech looked at startups poised to lead the economic recovery because of their technology, management team or growth potential. Cara Therapeutics is developing a novel analgesic pain reliever that the company said does not have the same central nervous system side effects of...
Purchase program for Melexis NV shares
August 31, 2010 8:34 pm | by I-Micronews | CommentsThe board of directors of Melexis Tessenderlo NV has decided on August 20, 2010 to start with the purchase of shares Melexis NV on Euronext Brussels (press release August 24, 2010).
